Bendamustine

CHEMBL487253 Phase 4 معتمد Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
358.3 g/mol
LogP
2.9
Phase
4

A chemotherapy agent with dual alkylating and antimetabolite properties that cross-links and breaks DNA strands in cancer cells, triggering cell death. It is used in lymphomas, chronic lymphocytic leukemia, and multiple myeloma.

الوزن الجزيئي

358,3000 g/mol

LogP

2,90

TPSA

58,40 Ų

قاعدة ليبينسكي للخمسة

ناجح

المجالات العلاجية

آلية العمل

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

الآلية

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing …

البنية ثنائية الأبعاد

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21

InChI

InChI=1S/C16H21Cl2N3O2/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23/h5-6,11H,2-4,7-10H2,1H3,(H,22,23)

Molecular Formula

C16H21Cl2N3O2

HBD / HBA

1 / 4

الروابط القابلة للدوران

9

الذرات الثقيلة

23

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

A chemotherapy agent with dual alkylating and antimetabolite properties that cross-links and breaks DNA strands in cancer cells, triggering cell death. It is used in lymphomas, chronic lymphocytic leukemia, and multiple myeloma.

Acts as an antimetabolite by incorporating into DNA or RNA or by inhibiting enzymes essential for nucleic acid synthesis. This disrupts DNA replication and causes cell death in rapidly dividing cells.

Yes, Bendamustine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL487253. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 65628. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.